Quick Takeaways
- Paradigm Biocapital Advisors LP filed SCHEDULE 13G for Maze Therapeutics, Inc. Common Stock, $0.001 par value per share (MAZE).
- Disclosed ownership: 6.1%.
- Date of event: 25 Mar 2026.
Paradigm Biocapital Advisors LP - 25 Mar 2026 SCHEDULE 13G Report for Maze Therapeutics, Inc. Common Stock, $0.001 par value per share (MAZE)
- Filing Manager
- Paradigm Biocapital Advisors LP
- Reporting Manager
- Paradigm BioCapital Advisors LP
- Symbol
- MAZE
- Shares outstanding
- 50,017,820 shares
- Disclosed Ownership
- 3,051,087 shares
- Ownership
- 6.1%
- Form type
- SCHEDULE 13G
- Filing time
- 01 Apr 2026, 16:00:37 UTC
- Date of event
- 25 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Paradigm Biocapital Advisors LP disclosed 6.1% ownership in Maze Therapeutics, Inc. Common Stock, $0.001 par value per share (MAZE) on 25 Mar 2026."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 01 Apr 2026, 16:00.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Paradigm BioCapital Advisors LP | 6.1% | 3,051,087 | 3,051,087 | 0 | /s/ David K. Kim | David K. Kim / Authorized Signatory | |
| Paradigm BioCapital Advisors GP LLC | 6.1% | 3,051,087 | 3,051,087 | 0 | /s/ David K. Kim | David K. Kim / Authorized Signatory | |
| Senai Asefaw, M.D. | 6.1% | 3,051,087 | 3,051,087 | 0 | /s/ Senai Asefaw, M.D. | N/A | |
| Paradigm BioCapital International Fund Ltd. | 5.4% | 2,688,520 | 2,688,520 | 0 | /s/ David K. Kim | David K. Kim / Authorized Signatory |